AmtixBio’s lead anti-inflammatory agent, ATB1606, is being developed for the treatment of atopic dermatitis (AD), the ... thymic stromal lymphoprotein (TSLP), which is overexpressed in AD ...

ORLANDO -- More than 80% of patients with moderate or severe atopic dermatitis (AD ... and the thymic stromal lipoprotein (TSLP) receptor, which is a key regulator of dendritic cell ...

Expert Rev Clin Immunol. 2013;9(3):211-216. Atopic dermatitis is a chronic inflammatory skin disease that commonly begins in early infancy, runs a course of exacerbations and remissions and is ...

Johnson & Johnson has reached an agreement to acquire a bispecific antibody for atopic dermatitis (AD ... agreement will give it rights to PX128, a TSLP and IL-13-targeting bispecific on the ...

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission. Raj Chovatiya ...

Proteologix’s lead candidate PX128 targets TSLP – currently drawing a lot of attention among drug developers – and IL-13, a well-validated target in atopic dermatitis, asthma, and other ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 10.08%, which has investors questioning if this is right time to sell.